Your browser doesn't support javascript.
Vaccines for COVID-19: Where do we stand in 2021?
Sharma, Ketaki; Koirala, Archana; Nicolopoulos, Katrina; Chiu, Clayton; Wood, Nicholas; Britton, Philip N.
  • Sharma K; National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, NSW, Australia.
  • Koirala A; National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, NSW, Australia; Department of Infectious Diseases, Nepean Hospital, Penrith, NSW, Australia.
  • Nicolopoulos K; National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia.
  • Chiu C; National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, NSW, Australia.
  • Wood N; National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, NSW, Australia.
  • Britton PN; Sydney Medical School, The University of Sydney, NSW, Australia; Department of Infectious Diseases and Microbiology, The Children's Hospital at Westmead, NSW, Australia. Electronic address: Philip.Britton@health.nsw.gov.au.
Paediatr Respir Rev ; 39: 22-31, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1307147
ABSTRACT
As of July 2021, over 3 billion doses of a COVID-19 vaccines have been administered globally, and there are now 19 COVID-19 vaccines approved for use in at least one country. Several of these have been shown to be highly effective both in clinical trials and real-world observational studies, some of which have included special populations of interest. A small number of countries have approved a COVID-19 vaccine for use in adolescents or children. These are laudable achievements, but the global vaccination effort has been challenged by inequitable distribution of vaccines predominantly to high income countries, with only 0.9% of people in low-income countries having received at least one dose of a COVID-19 vaccine. Addressing this inequity is of critical importance and will result in better control of SARS-CoV-2 globally. Other challenges include the reduced protection from COVID-19 vaccines against some strains of SARS-CoV-2, necessitating the development of variant specific vaccines; and uncertainties around the duration of protection from vaccine-induced immunity.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines / Variants Limits: Adolescent / Child / Humans Language: English Journal: Paediatr Respir Rev Journal subject: Pediatrics Year: 2021 Document Type: Article Affiliation country: J.prrv.2021.07.001

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines / Variants Limits: Adolescent / Child / Humans Language: English Journal: Paediatr Respir Rev Journal subject: Pediatrics Year: 2021 Document Type: Article Affiliation country: J.prrv.2021.07.001